CA
NZ
UK
AU
IND
US
…
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 521.47M | 45.36M | 105.60M | -410.42M | -215.74M |
| Minority interest | -0.82M | -0.44M | -0.31M | -0.45M | -27.61M |
| Net income | 457.02M | 37.73M | 100.78M | -410.14M | -227.66M |
| Selling general administrative | 103.03M | 64.30M | 79.78M | 92.17M | 89.30M |
| Selling and marketing expenses | - | 48.62M | 53.39M | 43.93M | 37.83M |
| Gross profit | 212.22M | 281.32M | 151.55M | 115.31M | 97.89M |
| Reconciled depreciation | 13.31M | 12.34M | 8.21M | 8.66M | 7.19M |
| Ebit | -54.59M | 1.76M | 59.07M | -409.77M | -336.46M |
| Ebitda | -41.28M | 14.11M | 67.27M | -401.11M | -329.27M |
| Depreciation and amortization | 13.31M | 12.34M | 8.21M | 8.66M | 7.19M |
| Operating income | -54.59M | -40.61M | 18.38M | -409.77M | -336.46M |
| Other operating expenses | 603.24M | 670.81M | 819.62M | 834.10M | 684.45M |
| Interest expense | 2.87M | 2.87M | 0.76M | 0.65M | 0.59M |
| Tax provision | 63.61M | 7.19M | 4.51M | -0.28M | 11.92M |
| Interest income | 49.88M | 40.08M | 36.15M | 9.60M | 2.08M |
| Net interest income | 47.01M | 37.21M | 35.39M | 8.95M | 1.48M |
| Income tax expense | 63.63M | 7.19M | 4.51M | -0.28M | 11.92M |
| Total revenue | 548.65M | 630.20M | 838.00M | 426.41M | 356.13M |
| Total operating expenses | 266.81M | 321.93M | 133.18M | 523.00M | 426.21M |
| Cost of revenue | 336.43M | 348.88M | 686.45M | 311.10M | 258.23M |
| Total other income expense net | 576.06M | 39.50M | 87.23M | -0.65M | 120.72M |
| Net income from continuing ops | 457.73M | 38.17M | 101.09M | -360.39M | -167.04M |
| Net income applicable to common shares | - | - | - | -360.83M | -194.65M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 1750.71M | 1274.20M | 1279.77M | 1029.44M | 1372.66M |
| Intangible assets | 8.93M | 167.74M | 116.89M | - | 0.16M |
| Other current assets | 11.10M | 12.30M | 43.35M | 152.20M | 164.62M |
| Total liab | 501.15M | 502.34M | 536.39M | 392.57M | 333.15M |
| Total stockholder equity | 1236.24M | 759.93M | 730.54M | 610.37M | 986.89M |
| Other current liab | 210.69M | 306.19M | 329.04M | 282.79M | 17.19M |
| Common stock | 87.11M | 87.16M | 87.13M | 86.48M | 86.45M |
| Capital stock | 87.23M | 87.16M | 87.13M | 86.48M | 86.45M |
| Retained earnings | -378.13M | -833.17M | -870.87M | -971.48M | -610.33M |
| Other liab | - | - | - | 15.37M | 14.33M |
| Good will | 3.11M | 2.99M | - | - | 3.38M |
| Other assets | - | - | - | 31.11M | 27.41M |
| Cash | 71.23M | 153.96M | 283.59M | 313.28M | 377.54M |
| Total current liabilities | 315.34M | 376.56M | 403.03M | 353.90M | 311.66M |
| Current deferred revenue | 31.37M | - | - | - | 226.38M |
| Net debt | 26.53M | -64.14M | -197.46M | -289.98M | -343.48M |
| Short term debt | 27.81M | 26.30M | 35.08M | - | 26.91M |
| Short long term debt | 24.97M | 23.37M | 31.16M | 0.00M | 26.91M |
| Short long term debt total | 97.76M | 89.82M | 86.13M | 23.30M | 34.07M |
| Other stockholder equity | 1531.78M | 1517.53M | 1514.28M | 1495.37M | 1510.77M |
| Property plant equipment | - | - | - | 84.67M | 53.15M |
| Total current assets | 1565.20M | 1066.56M | 1096.84M | 839.89M | 1212.08M |
| Net tangible assets | - | - | - | 610.37M | 983.35M |
| Short term investments | 1294.18M | 682.15M | 602.75M | 317.72M | 634.16M |
| Net receivables | 147.63M | 167.74M | 116.89M | 97.99M | 147.73M |
| Long term debt | 68.19M | 59.43M | 48.19M | 18.10M | 0.00M |
| Inventory | 41.07M | 50.40M | 50.26M | 56.69M | 35.76M |
| Accounts payable | 45.47M | 42.52M | 36.33M | 71.11M | 41.18M |
| Accumulated other comprehensive income | -4.53M | -11.59M | -8.16M | - | - |
| Non currrent assets other | 11.14M | 697.59M | 30.13M | 333.46M | 639.00M |
| Non current assets total | 185.50M | 207.64M | 182.93M | 189.56M | 160.59M |
| Capital lease obligations | 4.73M | 7.01M | 6.79M | 5.20M | 7.16M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -613.79M | -96.06M | -291.14M | 296.59M | -275.49M |
| Change to liabilities | - | - | - | 30.32M | 20.64M |
| Total cashflows from investing activities | -29.42M | -96.06M | -291.14M | 296.59M | -306.32M |
| Net borrowings | 6.26M | 5.61M | 61.70M | -9.17M | -0.58M |
| Total cash from financing activities | 7.84M | -30.67M | 48.66M | -82.76M | 650.03M |
| Change to operating activities | - | - | - | 64.04M | 63.46M |
| Net income | 457.02M | 38.17M | 101.09M | -360.39M | -167.04M |
| Change in cash | -94.28M | -129.63M | -29.69M | -64.26M | 141.91M |
| Begin period cash flow | 165.51M | 283.59M | 313.28M | 377.54M | 235.63M |
| End period cash flow | 71.23M | 153.96M | 283.59M | 313.28M | 377.54M |
| Total cash from operating activities | -64.67M | 0.50M | 219.26M | -268.60M | -204.22M |
| Issuance of capital stock | 1.58M | 0.79M | 5.09M | 0.17M | 717.32M |
| Depreciation | 13.31M | 12.34M | 8.21M | 8.66M | 7.19M |
| Other cashflows from investing activities | - | 1.28M | 29.50M | - | -15.00M |
| Change to inventory | 9.54M | -0.77M | 4.13M | -21.21M | -16.00M |
| Change to account receivables | 28.87M | -41.57M | -21.34M | -14.45M | -35.63M |
| Sale purchase of stock | 0.00M | -36.06M | -9.07M | -48.08M | -27.31M |
| Other cashflows from financing activities | - | -1.00M | -9.07M | -7.93M | -39.98M |
| Change to netincome | - | - | - | 24.85M | -49.27M |
| Capital expenditures | 14.15M | 17.93M | 32.61M | 36.66M | 16.76M |
| Change in working capital | -60.88M | -62.17M | 71.15M | 58.70M | 32.46M |
| Stock based compensation | 15.29M | 21.61M | 36.60M | 30.59M | 41.99M |
| Other non cash items | -474.13M | -9.45M | 1.60M | -6.17M | -3.68M |
| Free cash flow | -78.82M | -17.44M | 186.65M | -305.26M | -220.98M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(GBX) |
Price
(GBX) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| HCM HUTCHMED China Ltd |
-2.00 0.95% |
208.00 | 5.38 | 19.30 | 3.37 | 2.02 | 2.25 | 2.40 |
| HLN Haleon PLC |
-4.20 1.10% |
376.00 | 20.24 | 18.94 | 2.95 | 2.02 | 3.68 | 14.19 |
| HIK Hikma Pharmaceuticals PLC |
4.00 0.24% |
1704.00 | 9.73 | 9.03 | 0.85 | 1.45 | 1.53 | 6.07 |
| AGY Allergy Therapeutics |
- -% |
4.25 | - | 106.38 | 11.72 | 159.47 | 12.12 | -4.15 |
| STX Shield Therapeutics plc |
-0.17 3.09% |
5.33 | - | 65.36 | 2.24 | 76.33 | 3.34 | -1.49 |
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
| Name | Title | Year Born |
|---|---|---|
| Mr. Chi Keung To ACGI, B.Sc., BSc, M.B.A., MBA | Exec. Chairman | 1952 |
| Dr. Weiguo Su B.Sc., Ph.D. | CEO, Chief Scientific Officer & Exec. Director | 1957 |
| Mr. Chig Fung Cheng BEc, CA | CFO & Exec. Director | 1967 |
| Ms. Edith Shih C.S., CGP, FCS, M.A., P.E., BSE, EdM, Solicito | Company Sec. & Non-Exec. Director | 1952 |
| Dr. Karen Jane Atkin | Exec. VP & COO | 1966 |
| Mr. Kin Hung Lee M.B.A. | Sr. VP of Corp. Fin. & Devel. | 1977 |
| Mr. Charles George Rupert Nixon | Group Gen. Counsel | 1970 |
| Ms. Selina Zhang | Sr. VP of Global HR | NA |
| Dr. Qingmei Wang Ph.D. | Sr. VP of Bus. Devel. & Strategic Alliances | 1963 |
| Mr. Hong Chen | Sr. VP & Chief Commercial Officer- China | 1970 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.55%
Communication Services
-0.77%
Consumer Cyclical
-1.05%
Consumer Defensive
-0.33%
Energy
-2.55%
Financial Services
-1.62%
Financials
-0.80%
Healthcare
-2.85%
Industrials
-2.47%
Real Estate
-0.85%
Technology
-5.38%
Utilities
-0.83%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+31.04%
Please wait processing your request...